AVR 株価推移チャート
AVR 収入
Anteris Technologies Global Corp
$8.22
1.1%
$0.08
本日現在の状況：Jul 27, 15:34:41 GMT-4
戻る
Anteris Technologies Global Corp (AVR) 収入
最新の利益結果: Q1 '26
報告済み: 2026-05-12
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
AVRの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Anteris Technologies Global Corp AVRの前四半期の収益はどうでしたか？
Anteris Technologies Global Corpの収益見積もりはいくらですか？
Anteris Technologies Global Corpの収益品質スコアはどれくらいですか？
Anteris Technologies Global Corpはいつ収益を報告しますか？
Anteris Technologies Global Corpの予想収益はいくらですか？
Anteris Technologies Global Corpは収益予想を上回りましたか？
主要データ
前終値
$8.13
始値
$8.24
当日レンジ
$8.07 - $8.47
52週レンジ
$2.85 - $11.05
取引高
426.2K
平均取引高
1.1M
配当利回り
--
1株当たり利益(TTM)
-2.21
時価総額
$800.1M
AVRとは何ですか？
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 174 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The firm's ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
